Summary Circulating immune complexes (CICs) containing polymorphic epithelial mucin (PEM/MUC-J) were found in sera of 24.5% of 151 primary breast carcinoma patients and 18-21.4% of patients with advanced ovarian (n = 56) and breast carcinomas (n = 61), 37% of patients with benign breast tumours, but in only 2.1% of 96 healthy individuals. (Gendler et al., 1990; Lan. et al., 1990; Ligtenberg et al., 1990; Wreschner et al., 1990) , and each 20 amino acid repeat contains at least two potential 0-linkage sites. Utilisation of at least one of these sites during PEM biosynthesis, and subsequent elongation and branching of the attached 0-linked glycan, results in a heavily glycosylated molecule (Litvinov and Hilkens, 1993) .
Human polymorphic epithelial mucin (PEM) is a MUC-1 gene-encoded high molecular weight glycoprotein expressed by most glandular epithelia (for review see Hilkens et al., 1992) . The mucin-like extracellular domain of PEM consists, for the most part, of an array (from 30 to 90 among different alleles) of tandem repeats (Gendler et al., 1990; Lan. et al., 1990; Ligtenberg et al., 1990; Wreschner et al., 1990) , and each 20 amino acid repeat contains at least two potential 0-linkage sites. Utilisation of at least one of these sites during PEM biosynthesis, and subsequent elongation and branching of the attached 0-linked glycan, results in a heavily glycosylated molecule (Litvinov and Hilkens, 1993) .
In carcinomas, as a result of destruction of the original tissue architecture, PEM that is being shed from the carcinoma cells, enters the stroma and lymph and blood vessels, appearing in the bloodstream of patients. Levels of the circulating PEM are of significant value for monitoring carcinoma patients (Hilkens et al., 1986) . Several immunoassays are widely used for this purpose, among them CA 15-3 (Hayes et al., 1985) , CA M26 and CA M29 (Linsley et Yedema et al., 1991;  for review see Bon et al., 1990) . Most of these are 'sandwich' assays based on the application of two monoclonal antibodies recognising two different epitopes in the extracellular domain of the PEM molecule.
In 10-30% of breast and ovarian carcinoma patients with a high tumour load these assays detect low serum levels of PEM (Bon et al., 1990) , despite the fact that the protein is well expressed on carcinoma cells, as can be confirmed by immunohistological studies (Zotter et al., 1988) . One of the possible explanations for such a contradiction might be a masking effect produced by human autoantibodies that bind to the circulating PEM molecules, preventing an efficient detection of PEM in immunoassays.
Incomplete or deficient glycosylation of the PEM molecules has been demonstrated for carcinoma cells as compared with the normal tissue cou,nterpart (Girling et al., 1989; Hull et al., 1989; Litvinov and Hilkens, 1993) , and, as a result, antigenically changed PEM appears in circulation. Therefore, a specific humoral response against PEM peptide epitopes that are normally masked by glycosylation might be expected. A single case of a B-cell autoimmune response against PEM in a carcinoma patient was reported (Rughetti et al., 1993) . Additionally, the presence of autoantibodies reactive with various carbohydrate groups has been described in a substantial percentage of breast carcinoma patients (Barbacid et al., 1980 
SDS-PAGE and immunoblotting
For the detection of PEM, the immunoprecipitates were electrophoretically separated in 5% SDS-polyacrylamide gel MUC-1 mucin-containing immune complexes in carcinoma patients MM Gourevitch et al 935 (Laemmli, 1970) and subsequently transferred to a nitrocellulose membrane by electroblotting. The membranes were blocked by incubation in PBS/3% skim milk (2 h, room temperature). Filters were incubated for 2 -18 h at 4°C in MAb GPI.4 solution (5-10 jg ml' PBS/0.05% Tween 20), washed five to seven times in PBS/0. 05% Tween-20. The reacted murine antibodies were detected using the anti-mouse Protoblot system (Promega, Madison, WI, USA).
Results

Incidence of (PEM-CIC) in human sera
To detect the presence of CICs containing PEM in human sera we used the assay employing as catcher a PEM-specific MAb, and peroxidase-conjugated anti-human immunoglobulin antibodies as tracer. Since human sera may contain antibodies cross-reactive with murine IgG, we used normal mouse IgG as a control. For each serum the reaction in the control well (normal mouse IgG) was subtracted from the reaction in the experiment well (MAb 1 39H2), and the difference was considered to be a result of specific detection of PEM-containing CICs. The best sensitivity for the detection of PEM-CICs was obtained with a serum dilution 1:20. At higher dilutions only very high levels of PEM-CICs could be detected. The control subtraction approach was chosen because, with this dilution, background reactivity among individual sera still varied considerably. Background reactivity of sera with control murine IgG did not differ significantly (P = 0.5-0.8; Mann-Whitney U-test between different groups of donors (carcinoma patients and healthy controls). Background reactivity was also not affected by variations in CA 15-3 levels.
In the assay described above with MAb 139H2 as catcher, the PEM-CIC levels in sera of healthy controls were found to exceed values above 0.1 optical density (OD) units in only 2 of 96 cases (Figure 1 ). On this basis an upper level of normal PEM-CIC value of 0.1 OD was chosen, thus including 97.5% of the healthy population. With this cut-off level, 24.5% of primary breast carcinoma patients, and 18% and 21.4% of breast and ovarian carcinoma patients respectively, with advanced stage of disease were positive for the presence of PEM-CIC (Figure 1 ). Incidence of PEM-CIC in patients with benign breast tumours was even higher: 37% (Figure 1 ).
To verify our results, we also tested the same sera in a PEM-CIC assay employing as catchers two other monoclonal antibodies against PEM that differ in their epitopes on the PEM molecule: GPA.4 (isotype IgGl), and 11 5D8 (of IgG2a isotype). Most The results of the assay were reproducible when the aliquoted samples of sera were used since repetitive freezing-thawing of the sera affected the results of the assay greatly. The intra-assay coefficient of variation was between 5% and 11 % as expected in solid-phase immunoassays, interassay variations, however, were between 13% and 26%. The absence of a standard positive control that can be titrated and used as a reference in every test to obtain a calibration curve constitutes a problem. For this reason, evaluated results were obtained in a single assay.
Negative correlation between PEM-CIC and PEM levels Levels of circulating PEM were measured in all sera using the CA 15-3 assay and related to the level of PEM-CICs found for each serum.
Among ovarian carcinoma patients ( Figure 2a ) the highest levels of circulating PEM occurred in sera with relatively low levels of PEM-CIC. Those sera with the highest levels of estimated from immunoblots, the amount of PEM precipitated from two of these sera (one serum: Ot41; 5 U ml-', 0.27 OD presented in Figure 3 ) was relatively similar to that from an equal volume of serum with high level of CA 15-3 (140 U ml-', 0.27 OD, serum Mtl6, Figure  3 ). (Figure 4 ), suggesting that, at least in part, they appeared as a result of a specific immune response against the PEM molecules. Kotera et al. (1994) the peptide-representing repetitive domain of the PEM molecule. With respect to these data there is a question of whether anti-PEM antibodies involved in PEM-CICs are directed against protein epitopes on the PEM molecule or against the carbohydrate or against mixed carbohydrateprotein epitopes. The presence of antibodies to carbohydrate epitopes similar to those present on the PEM molecule in sera of carcinoma, patients was reported previously (Barbacid et al., 1980) , although it is difficult to determine whether their appearance is indeed an immune reaction against PEM. In this respect, it is important that recently (M Gourevitch et al. manuscript in preparation) a substantial number of sera used in the present study were found to be reactive with a synthetic peptide representing a triple tandem repeat from the repetitive domain of the PEM molecule. Such a peptide antigenic determinant represents a unique sequence of the PEM repeat in its natural conformation (Fontenot et al., 1993) , strongly suggesting a high specificity of human antibodies reactive with it. Nevertheless, the absence on the synthetic PEM repeat of 0-linked glycans, which are normally present on the PEM molecule, may affect the binding of a certain fraction of autoantibodies against PEM that recognise epitopes including carbohydrates chains; we cannot exclude the possibility that they cannot be detected using peptide antigenic determinant only. A further investigation of anti-PEM response is required to characterise the epitope specificity of autoantibodies, especially when considering an application of synthetic antigenic determinants of PEM for vaccination of carcinoma patients.
One plausible explanation for the appearance of anti-PEM autoantibodies in carcinoma patients is that PEM expressed in carcinoma cells is often aberrantly glycosylated or has low glycosylation (Girling et al., 1989; Hull et al., 1989; Hilkens et al., 1992; Litvinov and Hilkens, 1993) , and therefore carries both protein and carbohydrate epitopes which are not exposed on PEM synthesised by normal cells. In normal individuals immunogenic epitopes of PEM evade immunological recognition because they are masked by 0-linked glycans of the heavily glycosylated PEM molecule produced by normal glandular epithelia. The molecules with a changed antigenic profile might be immunogenic, as has been shown for some other proteins sharing common structural features with PEM. Thus, autoantibodies were found against leucosialin (Ardman et al., 1990 ), a highly 0-glycosylated leucocyte surface protein immunologically resembling PEM by combination of linear protein and carbohydrate epitopes. Also, autoantibodies reactive with a tandem repeat domain of the PEM molecule have been demonstrated in patients with ulcerative colitis (Hinoda et al., 1993) . A single case of humoral immune response against PEM was also recently reported by Rughetti et al. (1993) , who isolated a B-cell producing antibodies against PEM peptide epitope from an ovarian cancer patient. Cytotoxic lymphocytes reactive with PEM-expressing cells were found in an ovarian cancer patient (Ioannides et al., 1993) .
Another reason for the immune response against PEM, an antigen that is also expressed by normal tissue, is its increased exposure to the immune system in carcinoma patients. In normal tissue PEM is present almost exclusively at the apical domain of the glandular epithelia (Zotter et al., 1988) . During carcinogenesis tumour cells invade the stroma or metastasise into other tissues, constantly supplying PEM molecules to the immune presentation system of the patient. It is plausible to expect that incorporation of PEM into CICs would lead to enhanced consumption of the circulating PEM by macrophages or dendritic cells with the subsequent presentation of the PEM molecule to the immune system of the patient.
Little is known about glycosylation of PEM in cells of benign breast dysplasia or about the pathways of antigen supply into patients' circulation. Nevertheless, elevated levels of PEM can be detected in the circulation of such patients, as could be detected by the CA 15-3 assay (Bon et al., 1990) . Whether the high frequency of PEM-reactive antibodies detected in this group of patients can be explained in the same way as in carcinoma patients and whether the specificity of antibodies differs in patients with malignant and benign tumours are subjects for further investigation.
One of the important aspects of the results presented is an observed negative effect of binding of the PEM to CICs on its detection in commercially available immunoassays which are in clinical use for cancer monitoring. We have detected high levels of PEM-CICs in some sera in which only low levels of circulating PEM were found. As has been demonstrated here, the true levels of PEM might not be detected by the CA 15-3 assay as a result of a masking effect by human antibodies. This was confirmed by isolation of PEM molecules from sera that were low/negative in the CA15-3 assay; the real amounts of circulating PEM in those sera could correspond to the relatively high values of the CA 15-3 assay (Figure 3) .
The detection of circulating PEM in sera of carcinoma patients has proven to be important for monitoring of carcinoma patients (for review see Bon et al., 1990) . All immunoassays for PEM are based on the use of antibodies against epitopes in the repetitive domain of the PEM molecule. Usually between 3 and 10 MAbs (depending on the number of repeats) can react with the whole PEM molecule, and therefore all assays measure the number of free epitopes rather than the true number of PEM molecules. Developing the assay for PEM-CICs we presumed that at least a few epitopes on PEM, bound to CICs, are available for the binding of the catcher MAb, while not being sufficient for the effective binding of the tracer. This explanation seems to be correct, since we were able to detect PEM-CICs in human sera using not only MAb 139H2, but also 
